|
Outcomes for immuno-chemotherapy based treatment in patients with poorly differentiated extrapulmonary neuroendocrine carcinoma. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Faeth Therapeutics |
|
|
Employment - Illumina (I); Illumina (I) |
|
|
Honoraria - Aptitude Health |
Consulting or Advisory Role - Novartis Pharmaceuticals UK Ltd. |
|
|
Stock and Other Ownership Interests - Johnson & Johnson/Janssen |
Consulting or Advisory Role - Exelixis; Pfizer; QED Therapeutics |
Research Funding - Exelixis; Five Prime Therapeutics; Genentech; Incyte; Merck |
Travel, Accommodations, Expenses - Exelixis; QED Therapeutics |